Evidence map›Paper›PMID 32747827›Full record

ArticleNature medicine2020

Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda.

Aline Uwimana, Eric Legrand, Barbara H Stokes, Jean-Louis Mangala Ndikumana, Marian Warsame, Noella Umulisa, Daniel Ngamije, Tharcisse Munyaneza, Jean-Baptiste Mazarati, Kaendi Munguti and 8 more

Erratum issued Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07527182 (Confirmation of Artemisinin Partial Resistance in Plasmodium Falciparum Using WHO Criteria), which is not on this map. Cited by 473 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
473citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07527182 nacompletednot on this mapstarted 2024, after this paper: background citation

Confirmation of Artemisinin Partial Resistance in Plasmodium Falciparum Using WHO Criteria: A Multisite Clinical, Molecular and Phenotypic Study Across Five Sentinel Sites in Ethiopia, 2024-2025

TypeinterventionalSponsorDidier MenardRan2024 to 2026Enrolled277ConditionsMalaria (Plasmodium Falciparum), Drug Resistance, Artemisinin-resistant, EthiopiaArmsArtemether-Lumefantrine Tab 20-120mg
3 · Its place in the literature

Who cites it

473 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. A Systematic Review of Alternative Artemisinin Production Strategies.International journal of molecular sciences · 2025
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. N8-Modified Quino[4,3,2-Kl]acridines as Promising Antimalarial G-Quadruplex Ligands.Chembiochem : a European journal of chemical biology · 2026
    Article
  19. Article
  20. Article

413 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Aline Uwimana *Malaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre (RBC), Kigali, Rwanda. Aline.Uwimana@rbc.gov.rw.
Eric Legrand *Malaria Genetics and Resistance Unit-Institut Pasteur, INSERM U1201, CNRS ERL9195, Paris, France.ORCID http://orcid.org/0000-0003-4725-0712
Barbara H StokesDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, USA.ORCID http://orcid.org/0000-0001-9519-487X
Jean-Louis Mangala NdikumanaMalaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre (RBC), Kigali, Rwanda.
Marian WarsameUniversity of Gothenburg, Gothenburg, Sweden.
Noella UmulisaMaternal and Child Survival Program/JHPIEGO, Baltimore, MD, USA.
Daniel NgamijeMinistry of Health, Kigali, Rwanda.
Tharcisse MunyanezaNational Reference Laboratory (NRL), BIOS /Rwanda Biomedical Centre (RBC), Kigali, Rwanda.
Jean-Baptiste MazaratiNational Reference Laboratory (NRL), BIOS /Rwanda Biomedical Centre (RBC), Kigali, Rwanda.
Kaendi MungutiUS President's Malaria Initiative, Kigali, Rwanda.
Pascal CampagneHub de Bioinformatique et Biostatistique-Département Biologie Computationnelle, Paris, France.
Alexis CriscuoloHub de Bioinformatique et Biostatistique-Département Biologie Computationnelle, Paris, France.ORCID http://orcid.org/0000-0002-8212-5215
Frédéric ArieyINSERM 1016, Institut Cochin, Service de Parasitologie-Mycologie, Hôpital Cochin, Université de Paris, Paris, France.
Monique MurindahabiRoll Back Malaria for West and Central Africa, Kigali, Rwanda.
Pascal RingwaldGlobal Malaria Programme, World Health Organization, Geneva, Switzerland.
David A FidockDepartment of Microbiology and Immunology, Columbia University Irving Medical Center, New York, USA.
Aimable MbituyumuremyiMalaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre (RBC), Kigali, Rwanda.
Didier MenardMalaria Genetics and Resistance Unit-Institut Pasteur, INSERM U1201, CNRS ERL9195, Paris, France. dmenard@pasteur.fr.ORCID http://orcid.org/0000-0003-1357-4495

Funding

Defining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4M
Columbia University Graduate Training Program in Microbiology and ImmunologyT32AI106711 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Nicholas Arpaia, Uttiya Basu · 2014 to 2026
$2.1M
NIAID NIH HHS R01 AI109023NIAID NIH HHS T32 AI106711World Health Organization 001
6 · The paper itself

Abstract

Artemisinin resistance (delayed P. falciparum clearance following artemisinin-based combination therapy), is widespread across Southeast Asia but to date has not been reported in Africa

Indexed as

Mutation, MissenseAmino Acid SubstitutionAnimalsAntimalarialsArginineArtemisininsClonal EvolutionCommunicable Diseases, EmergingDrug ResistanceGenotypeHistidineHumansIn Vitro TechniquesKelch RepeatMalaria, FalciparumParasitic Sensitivity TestsAntimalarialsArginineartemisininArtemisininsHistidineProtozoan Proteins

Identifiers

PMID32747827
PMCPMC7541349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.